Arvinas, Inc. (ARVN) financial statements (2022 and earlier)

Company profile

Business Address 395 WINCHESTER AVE
NEW HAVEN, CT 06511
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,5031,544601651689249243
Cash and cash equivalents108256493465888922
Short-term investments1,3941,289552305100160221
Restricted cash and investments555    
Receivables26975864
Other undisclosed current assets2019158633
Total current assets:1,5531,576628665703258250
Noncurrent Assets
Operating lease, right-of-use asset4455222
Property, plant and equipment13121212121211
Other noncurrent assets  00000
Other undisclosed noncurrent assets1313     
Total noncurrent assets:29291617141413
TOTAL ASSETS:1,5821,605644682717272263
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities54181817261710
Accounts payable31559752
Accrued liabilities231413819127
Deferred revenue2061632222222123
Debt      1
Other undisclosed current liabilities111111 
Total current liabilities:2621834240494034
Noncurrent Liabilities
Long-term debt and lease obligation4446334
Long-term debt, excluding current maturities1112222
Operating lease, liability3334112
Liabilities, other than long-term debt5346001520232427
Deferred revenue5346001520232427
Total noncurrent liabilities:5386051926262731
Total liabilities:8007876166756765
Stockholders' equity
Stockholders' equity attributable to parent782818583615642205198
Common stock 000000
Additional paid in capital1,4691,4481,1671,1481,134654616
Accumulated other comprehensive income (loss)(5)(1)(0)(0)112
Accumulated deficit(683)(630)(583)(533)(492)(450)(420)
Total stockholders' equity:782818583615642205198
TOTAL LIABILITIES AND EQUITY:1,5821,605644682717272263

Income statement (P&L) ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues26966286
Gross profit:26966286
Operating expenses(81)(57)(57)(47)(45)(39)(32)
Operating loss:(54)(47)(52)(42)(43)(32)(26)
Nonoperating income1121211
Investment income, nonoperating1000111
Other nonoperating income1010100
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Loss before gain (loss) on sale of properties:(53)(47)(50)(41)(42)(31)(25)
Other undisclosed net income0  00  
Net loss:(53)(47)(50)(41)(42)(31)(25)
Other undisclosed net income attributable to parent 00  00
Net loss available to common stockholders, diluted:(53)(47)(50)(41)(42)(31)(25)

Comprehensive Income ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(53)(47)(50)(41)(42)(31)(25)
Comprehensive loss:(53)(47)(50)(41)(42)(31)(25)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(4)(0)(0)(1)(1)(1)2
Comprehensive loss, net of tax, attributable to parent:(57)(47)(51)(42)(42)(31)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: